• PD 173074 in Pancreatic Cancer: Pathway Inhibition & Prognos

  2026-05-27

  Explore how PD 173074, a potent FGFR1/VEGFR2 inhibitor, advances pancreatic cancer research through pathway suppression and integration with pyroptosis-based prognostic models. Discover protocol guidance and translational perspectives unique to this article.

• iPSC-Based Prescreening for Ultrarare Disease Clinical Trial

  2026-05-26

  Sequiera et al. introduce an induced pluripotent stem cell (iPSC) platform to personalize drug efficacy evaluation for ultrarare Leigh-like syndrome patients. Their approach enables functional prescreening of candidate therapeutics, improving the precision of clinical trial selection for individuals with novel genetic variants.

• Neticonazole Hydrochloride: A New Paradigm in Antifungal and

  2026-05-26

  Explore the multifaceted role of Neticonazole Hydrochloride as a leading imidazole antifungal with unique exosome inhibition and apoptosis modulation properties relevant to colorectal cancer research. This in-depth analysis integrates clinical guidance and advanced translational workflow, offering practical insights not found in prior reviews.

• Morin Inhibits AMPD2 to Protect Podocyte Mitochondria in Fru

  2026-05-25

  The reference study demonstrates that Morin, a natural flavonoid, alleviates fructose-induced podocyte injury by inhibiting adenosine 5′-monophosphate deaminase (AMPD2), thereby restoring mitochondrial energy metabolism. These findings highlight AMPD2 inhibition as a mechanistic target and suggest Morin's translational potential for diabetic kidney injury models.

• HBTU Enables High-Yield Zwitterionic Peptide Synthesis Workf

  2026-05-25

  HBTU streamlines the synthesis of advanced zwitterionic peptides with high selectivity and minimal racemization. This article dives into effective experimental workflows and troubleshooting tips, translating key innovations from recent cancer-selective peptide research into actionable lab strategies.

• 3-Methyladenine in Autophagy Inhibition: Protocols & Insight

  2026-05-24

  3-Methyladenine (3-MA) enables precise, reproducible autophagy inhibition and PI3K pathway dissection, supporting advanced cancer and virology research. This article distills workflow enhancements, troubleshooting, and unique insights from recent HBV studies to help you maximize experimental clarity.

• Nirmatrelvir (PF-07321332): Applied Workflows for SARS-CoV-2

  2026-05-23

  Nirmatrelvir (PF-07321332) enables precise, reproducible inhibition of SARS-CoV-2 replication in antiviral research models. This article details experimental protocols, troubleshooting strategies, and actionable insights for maximizing reliability when targeting the viral 3CL protease.

• Hematoxylin and Eosin Staining Kit: Protocol and QC Guide

  2026-05-22

  The Hematoxylin and Eosin Staining Kit (SKU: K1142) addresses the need for reproducible, ready-to-use solutions in histopathological and cytological tissue staining. It is ideal for visualizing tissue and cellular morphology in paraffin-embedded and frozen sections but should not be used for diagnostic or clinical purposes due to its research-only designation.

• G007-LK Tankyrase 1/2 Inhibitor: Precision Tools for β-Caten

  2026-05-22

  Explore how G007-LK, a selective tankyrase 1/2 inhibitor, enables advanced modulation of Wnt/β-catenin signaling and Hippo/YAP pathways in APC mutation colorectal cancer research. This article offers original insights on practical assay design, cross-pathway targeting, and translational oncology using G007-LK.

• Beyond the Benchmark: EZ Cap™ Firefly Luciferase mRNA in Nex

  2026-05-21

  Explore the advanced utility of EZ Cap™ Firefly Luciferase mRNA as a robust gene regulation reporter, with deep insights into translational efficiency, oxidative stress mitigation, and the latest assay innovations. Distinct from conventional guides, this article leverages new research to inform optimal mRNA delivery and experimental design.

• Propranolol and Emotional Memory: Meta-Analysis of Consolida

  2026-05-21

  This meta-analysis rigorously evaluates propranolol’s capacity to disrupt the consolidation and reconsolidation of long-term emotional memory in healthy adults. By synthesizing double-blind, placebo-controlled studies, the paper quantitatively demonstrates that propranolol—a non-selective β-adrenergic receptor blocker—can significantly attenuate recall of negatively valenced material. These findings suggest a mechanistic foundation for future interventions targeting pathological emotional memories.

• Synergistic Inhibition of PDAC via CDK4/6 and BET Pathway Mo

  2026-05-20

  Gu et al. reveal that combined CDK4/6 and BET inhibition synergistically suppresses pancreatic ductal adenocarcinoma (PDAC) growth and epithelial-to-mesenchymal transition by modulating the GSK3β-mediated Wnt/β-catenin pathway. This study clarifies the mechanistic basis for combination strategies in PDAC and highlights a promising therapeutic direction for overcoming the limitations of monotherapies.

• Imidazoline Antagonists Promote Insulin Release via K+ Chann

  2026-05-20

  Jonas et al. (1992) demonstrate that imidazoline antagonists of α2-adrenoceptors enhance insulin secretion in pancreatic β-cells primarily by inhibiting ATP-sensitive potassium channels, rather than through canonical adrenoceptor blockade. This mechanistic clarification informs the design of ion channel studies in diabetes research and highlights the value of targeted K+ channel inhibitors.

• Canagliflozin Alters Mitochondria in Diabetic Hypertensive K

  2026-05-19

  The reference study demonstrates that Canagliflozin, beyond its role in glycemic control, promotes structural and functional remodeling of mitochondria in proximal tubular cells of hypertensive–diabetic mice. These findings provide mechanistic insight into the kidney-protective effects of SGLT2 inhibition, with implications for diabetes and renal disease research.

• Machine Learning-Guided LNPs for mRNA Delivery to Microglia

  2026-05-19

  This study introduces a machine learning-driven approach to designing immunomodulatory lipid nanoparticles (LNPs) for targeted mRNA delivery to hyperactivated microglia. By integrating supervised classifiers and a diverse LNP library, the research demonstrates enhanced modulation of neuroinflammation, paving the way for precision therapies in neurodegenerative and autoimmune disorders.

454 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page